Please enable JS

Seth’s 50 State Network Advocate Talking Points: Prior Authorization

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

Seth’s 50 State Network Advocate Talking Points: Prior Authorization

Jun 09// Seth's 50 State Network Talking Points

1.      When a patient has to wait an extended period of time before beginning treatment, the patient, physician and public health suffers. 2.      The current system of prior authorization burdens the patient and physician leading to: a.       Delayed treatment and prolonged illness b.      Unstabilized care and the potential for permanent damage to occur c.       Diminished […]

READ MORE

Seth’s 50 State Network Advocate Brief: Prior Authorization

Jun 09// Memos Seth's 50 State Network

  How Can You Help?   Many states are currently introducing or revising legislation regarding prior authorization. Through your grassroots advocacy as part of the 50 State Network— online and in-person — the Prior Authorization message of poor outcomes, inefficiencies, and higher costs can be conveyed to:   State elected officials and staffers (legislators and […]

READ MORE

50 State Network Advocate Talking Points: Non-Preferred and Specialty Tier Drugs

Jun 09// Seth's 50 State Network Talking Points

1. As patients, our core concerns are to safeguard safety and the physician-patient relationship. 2. We believe only physicians should decide if a non-preferred or specialty tier drug is right for their patients. 3. Patients should pay the same for non-preferred drugs as they do for preferred drugs when it is the best or only […]

READ MORE

50 State Network Advocate Brief: Non-Preferred and Specialty Tier Drugs

Jun 09// Memos Seth's 50 State Network

How can you help? Help support bills that limit patients’ costs for specialty tier drugs. 87% of stand-alone Medicare Part D Prescription Drug Plans and 98% of Medicare Advantage-Prescription Drug Plans use specialty tiers, and this can be very expensive for those in need of special medicines. Patients who need non-preferred or specialty tier drugs […]

READ MORE

GHLF Supports AIR 340B Hospital Charity Care Analysis

Mar 25// Memos Seth's 50 State Network

The Global Healthy Living Foundation (GHLF) is excited to announce its support for the recent release of an Alliance for Integrity and Reform of 340B (AIR 340B) hospital charity care analysis entitled “Unfulfilled Expectations: An Analysis of Charity Care provided by 340B Hospitals”. Congress created the 340B program in 1992 to help uninsured, low-income patients […]

READ MORE

50 State Network Advocate Brief: Fail First/Step Therapy

Jan 29// Memos Seth's 50 State Network

How can you help? Currently, state governments across the country are holding hearings to debate the introduction, modification, or total removal of Fail First/Step Therapy policies in their state. Through your grassroots advocacy as part of the 50 State Network— online and in-person — the Fail First message of poor outcomes, inefficiencies, and higher costs […]

READ MORE

50 State Network Advocate Talking Points: Fail First/Step Therapy

Jan 29// Seth's 50 State Network Talking Points

  1. When a patient has to fail first on a drug before being allowed to take the medication originally prescribed, the patient, physician and public health suffers. 2. Fail first policies intrude on the patient/physician relationship and lead to: Prolonged illness Unstabilized care and the potential for permanent damage to occur Higher overall healthcare […]

READ MORE

GHLF Submits Letter to FDA Requesting Distinguishable Names for Biosimilars

Jan 13// Biosimilars Memos Seth's 50 State Network

On September 26th GHLF submitted a letter to Commissioner Hamburg at the FDA written by GHLF Chief Medical Officer, Dr. Jonathan Krant.  The letter explains that biosimilars are not like generic drugs. A biosimilar product is highly similar to, but not the same as it’s reference biologic product. Therefore, from a patient safety perspective, it is […]

READ MORE

50 State Network Advocate Talking Points: Biosimilars

Jan 04// Biosimilars Seth's 50 State Network Talking Points

As patients, our core concerns are to safeguard safety and the physician-patient relationship. Physicians and their patients are in the best position to determine appropriate therapies

READ MORE

50 State Network Advocate Brief: Biosimilars

Jan 04// Memos Seth's 50 State Network

In March 2010, a U.S. biosimilar pathway was signed into law as part of the Affordable Care Act (ACA). In February 2012, the Food and Drug Administration (FDA) issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States. What, if any, additional guidance FDA may issue, and when, is uncertain.

READ MORE